Claim Missing Document
Check
Articles

Found 2 Documents
Search

Lean Strategy for Optimizing Response Time in Hospital Code Blue Activation: A Two-Cycle Action Research in Central Java, Indonesia Habib Laksmana Prima; Merita Arini
Media Publikasi Promosi Kesehatan Indonesia (MPPKI) Vol. 9 No. 1 (2026): January 2026
Publisher : Fakultas Kesehatan Masyarakat, Universitas Muhammadiyah Palu

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56338/mppki.v9i1.8571

Abstract

ntroduction: Inefficiencies or delays in Code Blue activation for cardiac arrest patients contribute significantly to increased mortality. Rapid response time is closely associated with better prognosis. However, no previous study has systematically addressed the problem of Code Blue activation delay using a structured approach in hospital settings. This study aimed to formulate and implement improvement strategies to minimize waste and accelerate Code Blue activation. Methods: This research employed an action research design and adopted a two-cycle action research design to validate the application of Lean Management in optimizing Code Blue activation at a private Type D hospital in Banyumas, Central Java, Indonesia. A total of 11 consecutive Code Blue cases were observed in each cycle — 11 cases before (Cycle 1) and 11 cases after intervention (Cycle 2). Each cycle consisted of four stages: diagnosis, planning, action, and evaluation, guided by Value Stream Mapping (VSM) to identify and eliminate waste. Quantitative data (lead time, waiting time, cycle time, and Value-Added Ratio) were analyzed using Mann–Whitney tests, while qualitative insights were obtained from in depth interview and focus group discussions with 20 healthcare professionals. Results: The top three critical wastes identified in the baseline assessment were waiting (20.7%), defects (20.4%), and transportation (17%). Thus, waiting was concluded to be the most critical waste in the Code Blue activation process. Initially, the activation process had four phases: initial assessment by inpatient nurse, assessment by ward doctor, system activation, and arrival of the secondary team. After interventions, it was streamlined to three phases by removing the ward doctor’s assessment. Post-intervention, response time dropped by 92.2 % (from 122.1 to 9.5 minutes, p < 0.001), waiting time decreased by 91.3 % (from 50.7 to 4.4 minutes, p < 0.001), and the Value-Added Ratio (VAR) increased from 7 % to 39 % (p < 0.001). Conclusion: The implementation of Lean Management significantly reduces response time in Code Blue activation. Sustaining these improvements requires ongoing commitment and a multidimensional approach, including training, system evaluation, and strengthening a supportive work culture.
Neuroprotective and Disease-Modifying Potential of GLP-1 Receptor Agonists in Parkinson’s Disease: A systematic Review of randomized Controlled Trials and Cohort Study Rizqiana Arum Sari; Habib Laksmana Prima; Faishal Hanif
International Journal of Health Engineering and Technology Vol. 4 No. 5 (2026): IJHESS JANUARY 2026
Publisher : CV. AFDIFAL MAJU BERKAH

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55227/ijhet.v4i5.567

Abstract

Parkinson’s disease (PD) remains a progressive neurodegenerative disorder without established disease-modifying therapy. Recent evidence links insulin resistance, mitochondrial dysfunction, and neuroinflammation to PD pathogenesis, suggesting that metabolic modulation may provide neuroprotective benefits. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for diabetes, have emerged as potential agents that may slow neuronal loss and improve motor function through pleiotropic neuroprotective mechanisms. This systematic review aimed to synthesize clinical and observational evidence on the efficacy and safety of GLP-1 receptor agonists in Parkinson’s disease, focusing on motor progression, non-motor outcomes, and mechanistic implications. A comprehensive search of PubMed, the Cochrane Library, and ScienceDirect was conducted up to October 2025 using the keywords Parkinson AND (exenatide OR liraglutide OR lixisenatide OR semaglutide OR GLP-1 receptor agonist) combined with (randomized OR trial OR cohort). Eligible studies included randomized controlled trials and cohort analyses involving adult PD patients treated with GLP-1 receptor agonists compared to placebo or standard therapy. Data were narratively synthesized due to inter-study heterogeneity. GLP-1 receptor agonists were well tolerated, with gastrointestinal discomfort and mild weight loss as the most frequent adverse events. Six studies met inclusion criteria: five randomized controlled trials and one large multi center cohort. Early-phase exenatide trials reported sustained motor improvements lasting up to twelve months after treatment cessation, while the Lixisenatide phase 2 trial showed significant slowing of motor decline. Conversely, the phase 3 Exenatide-PD3 trial showed no significant difference from placebo. Observational data involving over five million patients indicated reduced neurodegenerative risk, particularly among semaglutide users. GLP-1 receptor activation appears to exert neuroprotective effects through multiple mechanisms, including mitochondrial restoration, suppression of neuroinflammation, and improvement of neuronal insulin signaling. Differences in CNS penetration, receptor affinity, and treatment duration likely account for the variability in clinical outcomes. While results remain heterogeneous, the biological plausibility and reproducible direction of benefit across independent studies underscore the potential of metabolic intervention as a viable disease-modifying strategy in PD. Safety profile and consistent mechanistic rationale position this drug class as a leading candidate for future disease-modifying therapy in neurodegeneration. GLP-1 receptor agonists demonstrate emerging promise as neuroprotective agents capable of slowing Parkinson’s disease progression. Although definitive evidence of disease modification awaits further confirmation from large multi center phase 3 trials.